The drug risks of cilostazol: A pharmacovigilance study of FDA Adverse Event Reporting System database

Lufeng Peng, Xueli Li, Junhai Li, Shibin Liu, Gang Liang · 2024

Read The drug risks of cilostazol: A pharmacovigilance study of FDA Adverse Event Reporting System database by Lufeng Peng, Xueli Li, Junhai Li, Shibin Liu, Gang Liang (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11616863.txt.

Description

Cilostazol is a drug used to ease leg pain from poor blood flow in the legs. Lufeng Peng and four co-authors mine a United States safety database to see what harms have been linked to the drug in real use. Their 2024 study covers reports from the first quarter of 2004 to the first quarter of 2024.

The team found 2,130 reports that named the drug as the main suspect, covering 7,134 adverse events in all. Most reports came from patients aged sixty and above. Using a standard odds method, they hunt for event types that show up more often than chance would suggest. The results aim to guide safer, more careful use of the drug in daily care.

Catalog record

CREATORLufeng Peng, Xueli Li, Junhai Li, Shibin Liu, Gang Liang
YEAR2024
COLLECTIONPAPERS
FORMATTXT
FILE SIZE37 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11616863

Browse the full library · About the Tower of Babel